Christopher M. Starr - 01 Oct 2026 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Reporting relationship: Director
Issuer ticker: MNPR
Reported as of: 01 Oct 2026
Net transaction value: -$659,387
SEC form: 4
Accepted by SEC: 05 Oct 2026, 17:43:27 UTC
Prior SEC filing: 08 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Quan Vu, Attorney-in-fact

Key filing fact

Christopher M. Starr filed Form 4 for Monopar Therapeutics (MNPR) on 05 Oct 2026.

Key facts

This page summarizes Christopher M. Starr's Form 4 filing for Monopar Therapeutics (MNPR).
5 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 Oct 2026, 17:43.

Change

Previous filing in this sequence was filed on 08 Dec 2025.
Current net transaction value: -$659,387.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001235470 Primary reporting owner

STARR CHRISTOPHER M

Relationship: Director
Address: 1000 SKOKIE BLVD SUITE 350, WILMETTE
Signature: /s/ Quan Vu, Attorney-in-fact
Signature date: 05 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MNPR transaction

Common Stock

Options Exercise

Transaction value
Shares: +8,400
Change %: +162%
Price: $0.005000^*
Shares after: 13,573
Date: 01 Oct 2026
Ownership: Direct
Footnotes: F1

MNPR transaction

Common Stock

Sale

Transaction value: $361,635
Shares: -4,631
Change %: -34%
Price: $78.09
Shares after: 8,942
Date: 01 Oct 2026
Ownership: Direct
Footnotes: F1, F4

MNPR transaction

Common Stock

Sale

Transaction value: $234,095
Shares: -2,970
Change %: -33%
Price: $78.82
Shares after: 5,972
Date: 01 Oct 2026
Ownership: Direct
Footnotes: F1, F5

MNPR transaction

Common Stock

Sale

Transaction value: $63,656
Shares: -799
Change %: -13%
Price: $79.67
Shares after: 5,173
Date: 01 Oct 2026
Ownership: Direct
Footnotes: F1, F6

MNPR holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 9,880
Date: 01 Oct 2026
Ownership: See Footnote
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MNPR transaction Derivative

Stock Option

Options Exercise

Transaction value
Shares: -8,400
Change %: -50%
Price: $0.000000^*
Shares after: 8,400
Date: 01 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,400
Exercise price: $0.005000
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 6 footnotes

Footnote F1

This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 28, 2026.

Footnote F2

On February 20, 2017, the reporting person was granted stock options to purchase up to 16,800 shares of common stock. Stock options vest 6/48ths on the six-month anniversary of grant date and 1/48th per month thereafter.

Footnote F3

Represents shares of common stock held by the Christopher M. Starr and Sheri L. Starr Revocable Trust over which Dr. Starr serves as Trustee.

Footnote F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.50 to $78.49, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.

Footnote F5

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.50 to $79.49, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.

Footnote F6

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.50 to $80.01, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.